Rare diseases
Investigational molecules
Locations
147 conditions with trials, the busiest first
548 trials across Europe, recruiting first
Phase 3 Study of Pitolisant for Excessive Daytime Sleepiness in Narcolepsy Patients
BelgiumStudy of Brenipatide (LY3537031) in Adults with Major Depressive Disorder to Evaluate Delay of Relapse Compared with Placebo
GermanyEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
AustriaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaA study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease
CzechiaOrforglipron for stress urinary incontinence in women with obesity or overweight
CzechiaA study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease
CzechiaStudy of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation
BulgariaStudy of evenamide as add-on treatment for patients with treatment-resistant schizophrenia not adequately controlled by current antipsychotic medications
BulgariaStudy of tasimelteon compared to placebo for treating insomnia in children
GermanyStudy on ITI-1284 for Patients with Generalized Anxiety Disorder Who Did Not Respond Well to Previous Treatments
BulgariaThe therapies tested most often in Psychiatric disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
